Oragenics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Oragenics, Inc. on December 19, 2018. The report addresses Item 5.02 regarding compensatory arrangements for certain officers. The Company is incorporated in Florida and operates from Tampa, FL.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation adjustments.
Material Changes
The Board of Directors approved 2019 annual base salaries for named executive officers, effective January 1, 2019. The approved salaries are as follows:
- Dr. Alan Joslyn (President and CEO): $367,500
- Mr. Michael Sullivan (CFO): $229,950
- Dr. Martin Handfield (SVP Discovery Research): $205,380
The filing text does not provide the prior year (2018) salary figures for these individuals to calculate specific percentage changes, though it references a table for 2017 salaries which is not populated in the provided text.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. The report is limited to the administrative approval of executive compensation.
Investor Verification Checklist
- Verify the total increase in annual compensation expense resulting from these salary adjustments.
- Confirm if these salary changes were accompanied by adjustments to bonus targets or equity awards.
- Review the Company's most recent 10-K or 10-Q to compare these new base salaries against historical compensation trends.